At a glance
ClinicalIndex Comparison Record- ✓English or Spanish-speaking women over 18 years old
- ✓Eligible for non-urgent D&E at 16 0/7 to 20 6/7 weeks gestation confirmed by ultrasound
- ✓Willing and able to provide informed consent
- ✕Emergent need for D&E
- ✕Intrauterine infection
- ✕Fetal demise
- ✕Molar pregnancy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-blinded Comparison of 24-hour Interval-Mifepristone and Buccal Misoprostol Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation in Second-Trimester Surgical Abortion
In Brief
A Phase 4 clinical trial evaluating Vaginal Misoprostol and Buccal Misoprostol for Abortion, Second Trimester. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This study aims to compare mifepristone and buccal misoprostol to mifepristone and vaginal misoprostol for cervical preparation for second trimester dilation and evacuation (D\&E).
Study Details
Timeline
Interventions
Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E
Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E